10-May-2024
No Comments
Cellaïon Announces Discontinuation of Phase 2b Clinical Trial in Acute on Chronic Liver Failure with HepaStem®
Menu
Cellaïon Announces Discontinuation of Phase 2b Clinical Trial in Acute on Chronic Liver Failure with HepaStem®
Cellaïon SA appoints new Chief Executive Officer to drive Clinical & Commercial development
Cellaïon SA announces an additional closing of 5,5M Euros financing on June 13th 2023.
Cellaïon SA announces the arrival of Walid Abi-Saab in its Board of Directors, the hiring of Griet Goddemaer to lead clinical development and the green light from the DSMB for the continuation of ACLF- Dheliver Clinical trial.
Cellaïon announces update to its Board of Directors:
Dr. Fouzia LAGHRISSI-THODE joins the biotech as Member of the Board